Preview

Epilepsy and paroxysmal conditions

Advanced search

A relation between the quality of life of patients with epilepsy and adherence to treatment as well as retention on therapy

https://doi.org/10.17749/2077-8333/epi.par.con.2022.069

Abstract

Objective: to demonstrate  the mutual influence  of  the quality of  patients’s life  during  epilepsy, adherence  to received anticonvulsant therapy and retention on therapy.

Material and methods. We conducted an analytical review of studies published by foreign authors in recent years (published within 2016–2021  were considered of top priority), devoted to the influence of various factors on adherence to therapy in patients with epilepsy. A search for relevant publications was conducted in English-language databases (PubMed/MEDLINE, ClinicalKey) by using key words and phrases: “epilepsy AND quality of life AND adherence  to therapy”, “epilepsy AND quality of life AND retention on  therapy”,  “epilepsy AND adherence   to therapy”, “compliance AND epilepsy  AND quality of  life”, “adherence to therapy AND retention on therapy AND epilepsy”, “nonadherence to therapy AND epilepsy  AND quality of life”. After the selection procedure, 22 scientific publications were included in the review.

Results. Factors that have a negative impact on adherence  to therapy have been identified (comorbid cognitive impairment, the combination of lack of control over seizures and the presence of adverse events after drug administration, depression and anxiety, the need to change the lifestyle for taking the drug, concern about the potential negative consequences of taking the drug, recent uncontrolled seizures, lack of professional implementation, high frequency of taking the drug, problems with doctor-patient relationship, insufficient social support), and factors that have a positive impact (emotional support from the doctor, establishing doctor-patient partnership).

Conclusion. There is a relationship between the patient's quality of life and adherence  to therapy. Patient adherence to therapy is important for the effectiveness of epilepsy treatment and, along with the severity of epilepsy, is a significant factor affecting the quality of patients’ life during epilepsy. An opportunity for long-term retention on anticonvulsant therapy also has a cross-correlation with quality of life.

About the Author

I. V. Lusnikova
Pirogov Russian National Research Medical University
Russian Federation

Iya V. Lusnikova – MD, PhD, Associate Professor, Chair of Neurology, Neurosurgery and Medical Genetics, Faculty of Medicine, Pirogov Russian National Research Medical University.

1 Ostrovityanov Str., Moscow 117513.

RSCI SPIN-code: 5284-5767



References

1. WHOQOL: Measuring quality of life. Geneva: World Health Organization; 1997. Available at: https://apps.who.int/iris/bitstream/handle/10665/63482/WHO_MSA_MNH_PSF_97.4.pdf?sequence=1&isAllowed=y (accessed 17.01.2022).

2. Neznanov N.G., Gromov S.A., Mikhailov V.A., et al. Epilepsy, quality of life, treatment. St. Petersburg: VMA; 2005: 294 pp. (in Russ.).

3. Gromov S.A., Begi E., Mikhailov V.A., Lipatova L.V. Epidemiology of epilepsy and the risk of deterioration in the quality of life of patients. The Neurological Journal. 1996; 1 (2): 27–30 (in Russ.).

4. Duncan J.C. Medical factors affecting quality of life in patients with epilepsy. In: Chadwick D. (Ed.) Quality of life and quality of care in epilepsy. Oxford: Alden Press; 1990: 80–7.

5. Karlov V.А. Epilepsy in children and adult women and men. A guide for doctors. Мoscow: Meditsina; 2010: 720 pp. (in Russ.).

6. Karlov V.А. Epilepsy in children and adult women and men. A guide for doctors. Мoscow: BINOM; 2019: 896 pp. (in Russ.).

7. Ayanda K.A., Sulyman D. Determinants of quality of life in adults living with epilepsy. Ann Afr Med. 2020; 19 (3): 164–9. https://doi.org/10.4103/aam.aam_20_18.

8. Cramer J.A., Perrine K., Devinsky O., et al. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia. 1998; 39 (1): 81–8. https://doi.org/10.1111/j.1528-1157.1998.tb01278.x.

9. Guekht A., Gusev E., Kurkina I., et al. Epidemiology and quality of life of epilepsy patients in Moscow, Russia. Eur J Neurol. 2000; 7 (Suppl. 3): 13.

10. Cramer J., Perrine K., Devinsky O., Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia. 1996; 37 (6): 577–82. https://doi.org/10.1111/j.1528-1157.1996.tb00612.x.

11. Leppik I.E. Сompliance during treatment of epilepsy. Epilepsia. 1988; 29 (Suppl. 2): S79–84. https://doi.org/10.1111/j.1528-1157.1988.tb05801.x.

12. Belousova E.D. The problem of compliance in patients with epilepsy. Russian Medical Journal. 2009; 17 (5): 380–3 (in Russ.).

13. Lutova N.B., Neznanov N.G., Vid V.D. Compliance in psychiatry and a way to assess it. Psychiatry and Psychopharmacotherapy. 2008; 10 (1): 8–12 (in Russ.).

14. Avakyan G.N., Belousova E.D., Burd S.G., et al. Current trends in epileptology: priorities, challenges, tasks and solutions. Epilepsia i paroksizmalʹnye sostoania / Epilepsy and Paroxysmal Conditions. 2019; 11 (4): 395–406 (in Russ.). https://doi.org/10.17749/2077-8333.2019.11.4.395-406.

15. Mironenko Yu.E., Mikhailov V.A., Lipatova L.V., et al. Clinical, social and psychological aspects of compliance in locally conditioned epilepsy. In: Neznanov N.G., Mikhailov V.A. (Eds.) Epileptology in the system of neuroscience. Collection of conference abstracts. St. Petersburg; 2015: 131–2 (in Russ.).

16. Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu. Treatment adherence: modern view on a well known issue. Cardiovascular Therapy and Prevention. 2017; 16 (1): 91–5 (in Russ.). http://doi.org/10.15829/1728-8800-2017-1-91-95.

17. O’Rourke G., O’Brien J.J. Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure. 2017; 45: 160–8. http://doi.org/10.1016/j.seizure.2016.12.006.

18. Faught R.E., Duh M.S., Weiner J.R., et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology. 2008; 71 (20): 1572–8. http://doi.org/10.1212/01.wnl.0000319693.10338.b9.

19. Skinner H.J., Durbon-Murcia S.A., Thompson A.R., et al. Adult convulsive status epilepticus in the developing country of Honduras. Seizure. 2010; 19 (6): 363–7. http://doi.org/10.1016/j.seizure.2010.05.007.

20. Lathers C.M., Koehlar S.A., Wecht C.H., Schraeder P.L. Forensic antiepileptic drug levels in autopsy cases of epilepsy. Epilepsy Behav. 2011; 22 (4): 778–85. http://doi.org/10.1016/j.yebeh.2011.10.011.

21. Guekht A.B. Quality of life of patients with epilepsy. In: International Conference “Epilepsy – Diagnosis, Treatment, Social Aspects”. Мoscow; 2005: 120–5 (in Russ.).

22. Kwan P., Schachter S.C., Brodie M.J. Drug-resistant epilepsy. N Engl J Med. 2011; 365: 919–26. http://doi.org/10.1056/NEJMra1004418.

23. Henning O., Johannessen Landmark C., Nakken K.O., Lossius M.I. Nonadherence to treatment regimens in epilepsy from the patient's perspective and predisposing factors: differences between intentional and unintentional lack of adherence. Epilepsia. 2019; 60 (5): e58–62. https://doi.org/10.1111/epi.14734.

24. Banks J., Varley J., Fitzsimons M., Doherty C.P. Self-reported antiepilepsy medication adherence and its connection to perception of medication error. Epilepsy Behav. 2020; 104 (Pt. A): 106896. https://doi.org/10.1016/j.yebeh.2019.106896.

25. Chapman S.C.E., Horne R., Chater A., et al. Patients' perspectives on antiepileptic medication: Relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care. Epilepsy Behav. 2014; 31: 312–20. https://doi.org/10.1016/j.yebeh.2013.10.016.

26. Kuzmanova R., Stefanova I., Stambolieva K. Significance of noncompliance when treating patients with epilepsy. Neurol Neurochir Pol. 2018; 52 (2): 215–21. https://doi.org/10.1016/j.pjnns.2017.10.005.

27. May T.W., Berkenfeld R., Dennig D., et al. Patients’ perspectives on management and barriers of regular antiepileptic drug intake. Epilepsy Behav. 2018; 79: 162–8. https://doi.org/10.1016/j.yebeh.2017.11.039.

28. Ferrari C.M., Cardosa de Sousa R.M., Castro L.H. Factors associated with treatment non-adherence in patients with epilepsy in Brazil. Seizure. 2013; 22 (5): 384–9. https://doi.org/10.1016/j.seizure.2013.02.006.

29. Voronkova K.V., Pylaeva O.A., Kholin A.A., et al. Side-effects of antiepileptic treatment: the current state of the problem. S.S. Korsakov Journal of Neurology and Psychiatry. 2011; 111 (10-2): 44–51 (in Russ.).

30. Laville F., Montana M., Roux N., et al. Factors limiting adherence to antiepileptic treatment: a French online patient survey. J Clin Pharm Ther. 2018; 43 (1): 73–9. https://doi.org/10.1111/jcpt.12615.

31. Hamer H., Baulac M., McMurray R., Kockelmann E. Retention, dosing, tolerability and patient reported seizure outcome of Zonisamide as only add-on treatment under real-life conditions in adult patients with partial onset seizures: results of the observational study ZOOM. Seizure. 2016; 34: 66–73. https://doi.org/10.1016/j.seizure.2015.12.001.

32. Brodie M.J., Mintzer S., Pack A.M., et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013; 54 (1): 11–27. https://doi.org/10.1111/j.1528-1167.2012.03671.x.

33. Zeber J.E., Tang F., Zhu G., et al. Self-reported adherence in patients with epilepsy who missed their medications and reasons for nonadherence in China. Epilepsy Behav. 2013; 27 (1): 85–9. https://doi.org/10.1016/j.yebeh.2012.12.022.

34. Sweileh W.M., Ihbesheh M.S., Jarar I.S., et al. Selfreported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav. 2011; 21 (3): 301–5. https://doi.org/10.1016/j.yebeh.2011.04.011.

35. Copeland L.A., Pugh M.J. Variation in antiepileptic drug adherence among older patients with new-onset epilepsy. Ann Pharmacother. 2010; 44 (12): 1896–904. https://doi.org/10.1345/aph.1P385.

36. Harimanana A., Clavel S., Chivorakul P., et al. Associated factors with adherence to antiepileptic drug in the capital city of Lao PDR. Epilepsy Res. 2013; 104 (1–2): 158–66. http://doi.org/10.1016/j.eplepsyres.2012.10.008.

37. Buck D., Jacoby A., Baker G.A., Chadwick D.W. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997; 6 (2): 87–93. http://doi.org/10.1016/s1059-1311(97)80060-x.

38. Honnekeri B., Rane S., Vast R., Khadilkar S.V. Between the person and the pill: factors affecting medication adherence in epilepsy patients. J Assoc Physicians India. 2018; 66 (7): 24–6.

39. Ben-Menachem E., Grebe H.P., Terada K., et al. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Epilepsia. 2019; 60 (12): 2437–47. http://doi.org/10.1111/epi.16381.

40. Mäkinen J., Peltola J., Raitanen J., et al. Comparative effectiveness of eight antiepileptic drugs in adults with focal refractory epilepsy: the influence of age, gender, and the sequence in which drugs were introduced onto the market. J Neurol. 2017; 264 (7): 1345–53. http://doi.org/10.1007/s00415-017-8526-8.

41. Shafiqur R., Syed A.A., Syeda J.K., et al. Comparison of anti-epileptic drugs in terms of treatment outcomes, adverse effects and quality of life. J Clin Diagnostic Res. 2019; 13 (10): FC01–7. http://doi.org/10.7860/jcdr/2019/41895.13228.

42. Lin C.Y., Chen H., Pakpou A.H. Correlation between adherence to antiepileptic drugs and quality of life in patients with epilepsy: a longitudinal study. Epilepsy Behav. 2016; 63: 103–8. http://doi.org/10.1016/j.yebeh.2016.07.042.


Review

For citations:


Lusnikova I.V. A relation between the quality of life of patients with epilepsy and adherence to treatment as well as retention on therapy. Epilepsy and paroxysmal conditions. 2022;14(1):65-73. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2022.069

Views: 727


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)